ENYX

ENYO Pharma is a clinical-stage biotechnology company that utilizes a unique drug discovery engine inspired by virus-host interactions. By mimicking the strategies viruses use to hijack host cellular functions, the company identifies novel therapeutic targets and develops small molecule modulators for difficult-to-treat diseases. Their lead candidate, Vonafexor, is a highly selective farnesoid X receptor (FXR) agonist currently being evaluated in Phase 2 clinical trials for Alport syndrome and other kidney-related fibrotic diseases. The company's innovative approach aims to address significant unmet needs in hepatology, nephrology, and infectious diseases.